News

A new test that recognizes anti-neutrophil cytoplasmic autoantibodies (ANCAs) targeting proteins other than myeloperoxidase (MPO) and proteinase-3 (PR-3) could improve the diagnosis and classification of ANCA-associated vasculitis, a study suggests. The study, “ANCA Beyond MPO & PR-3: the Clinical Utility of an Expanded ANCA Profile,” was recently presented at…

Genentech‘s Rituxan (rituximab) is safe and effective to induce and maintain remission in patients with refractory or relapsing granulomatous manifestations (inflamed tissue) due to granulomatosis with polyangiitis (GPA), according to a new study. The findings were presented at the recent 19th International Vasculitis and ANCA Workshop in Philadelphia, Pennsylvania,…

Intravenous immunoglobulin therapy – which essentially consists on pooled antibodies from a thousand or more blood donors – could be a promising way of treating MPO-positive ANCA-associated vasculitis patients, an early study suggests. In a rat model of the disease, this therapy lowered the number of anti-MPO antibodies, reduced neutrophil traps –…

Eosinophils, a type of immune cell, appear to contribute to the inflammatory process seen in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), a study shows. The study, “Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis,” was published in the journal BMC Rheumatology. ANCA-associated…

A large proportion of patients with ANCA-associated vasculitis (AAV) who develop orbital mass, an eye complication, respond poorly to treatment, a study reports. Future studies need to evaluate the use and effectiveness of combination therapies for the subgroup of patients that are more likely to develop this condition, according…